PMID- 25233818
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20221207
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 28
IP  - 12
DP  - 2014 Dec
TI  - Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated 
      periorbitopathy with a latanoprost ophthalmic solution.
PG  - 1446-51
LID - 10.1038/eye.2014.224 [doi]
AB  - PURPOSE: Among some local side effects of prostaglandin-associated 
      periorbitopathy (PAP), deepening of the upper eyelid sulcus (DUES) is the most 
      prominent clinical feature, and is one of the most significant adverse cosmetic 
      events. Here, we prospectively investigated the incidence of DUES in Japanese 
      open-angle glaucoma patients initially treated with latanoprost (Xalatan 0.005%) 
      ophthalmic solution. METHODS: This was an open-label prospective study. Facial 
      photographs and subjective reports of the recognition of DUES were obtained at 
      the beginning of latanoprost treatment and at 2, 4, and 6 months thereafter. 
      Intraocular pressure (IOP) was measured at three consecutive visits before and 
      after treatment with latanoprost. The incidence of DUES was evaluated objectively 
      by three blinded investigators who compared the series of photographs. RESULTS: A 
      total of 52 eyes of 52 newly diagnosed open-angle glaucoma Japanese patients (28 
      males, 24 females) were evaluated. The objective rate of DUES was 1/52 (2%; 95% 
      CI 0.05 to 10.7%) at 2 months, 2/52 (4%; 95% CI 0.5 to 13.9%) at 4 months, and 
      3/52 (6%; 95% CI 1.2 to 16.9%) at 6 months. During this period, no patient 
      self-reported an occurrence of DUES. Mean IOPs before and after treatment were 
      16.5+/-2.9 and 13.8+/-3.0 mm Hg, respectively. Latanoprost reduced the IOP 
      significantly (P<0.0001, paired t-test). CONCLUSIONS: Latanoprost caused DUES 
      rarely and had a robust IOP-lowering effect in Japanese glaucoma patients.
FAU - Sakata, R
AU  - Sakata R
AD  - 1] Department of Ophthalmology, University of Tokyo, Tokyo, Japan [2] Tokyo 
      Metropolitan Geriatric Hospital, Tokyo, Japan.
FAU - Shirato, S
AU  - Shirato S
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
FAU - Miyata, K
AU  - Miyata K
AD  - Miyata Eye Hospital, Miyazaki, Japan.
FAU - Aihara, M
AU  - Aihara M
AD  - 1] Department of Ophthalmology, University of Tokyo, Tokyo, Japan [2] Yotsuya 
      Shirato Eye Clinic, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140919
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 6Z5B6HVF6O (Latanoprost)
SB  - IM
MH  - Antihypertensive Agents/*adverse effects
MH  - Asian People/ethnology
MH  - Eyelid Diseases/*chemically induced
MH  - Face
MH  - Female
MH  - Glaucoma, Open-Angle/*drug therapy/ethnology
MH  - Humans
MH  - Incidence
MH  - Intraocular Pressure/*drug effects
MH  - Japan
MH  - Latanoprost
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Solutions
MH  - Orbital Diseases/*chemically induced
MH  - Photography
MH  - Prospective Studies
MH  - Prostaglandins F, Synthetic/*adverse effects
PMC - PMC4268464
EDAT- 2014/09/23 06:00
MHDA- 2015/06/04 06:00
PMCR- 2015/12/01
CRDT- 2014/09/20 06:00
PHST- 2014/05/06 00:00 [received]
PHST- 2014/08/08 00:00 [accepted]
PHST- 2014/09/20 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
PHST- 2015/12/01 00:00 [pmc-release]
AID - eye2014224 [pii]
AID - 10.1038/eye.2014.224 [doi]
PST - ppublish
SO  - Eye (Lond). 2014 Dec;28(12):1446-51. doi: 10.1038/eye.2014.224. Epub 2014 Sep 19.